A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

Overview of attention for article published in Hematological Oncology, October 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 17 Mendeley

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 4,324 followers.

A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma https://t.co/4k6msw8ib6 #ScientiaVH

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma - Carlo‐Stella - 2023 - Hematological Oncology - Wiley Online Library https://t.co/uHxJ8fD8yT

A Phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma No caso concreto da doente incluída por nós, o estudo permitiu-lhe controlo de doença. Nem todos os estudos negativos são maus para todos! …

New article: A Phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma https://t.co/b37fiScr2y #DLBCL #lymsm #hematology https://t.co/ftgERR7oHT

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.